Clinical trial · Interventional
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc
NCT00005853CI-TRIAL-00003319completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients who have myelodysplastic syndrome.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anti-thymocyte globulin | Biological | — | UNRESOLVED |
| etanercept | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of myelodysplastic syndrome with no greater than 20% marrow blasts with:
* Single or multilineage cytopenia (neutrophils less than 2,000/mm\^3 and/or platelet count less than 100,000/mm\^3 and/or reticulocyte count less than 18,000/mm\^3) OR
* Transfusion requirement of at least 2 units packed red blood cells per month and one of the following:
* Suitable marrow donor unavailable
* Ineligible for a transplantation protocol
* Unwilling to proceed with transplantation
* No chronic myelomonocytic leukemia
PATIENT CHARACTERISTICS:
Age:
* Any age
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* See Disease Characteristics
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No other severe disease that would preclude study
* No active severe infection (e.g., pneumonia or septicemia) or severe infections within the past 2 weeks
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* See Disease Characteristics
* At least 4 weeks since prior hematopoietic growth factors
* No concurrent hematopoietic growth factors
Chemotherapy:
* At least 4 weeks since prior cytotoxic therapy
* No concurrent cytotoxic therapy
Endocrine therapy:
* Not specified
Radiation therapy:
* Not specified
Surgery:
* Not specified
Other:
* At least 4 weeks since prior immunomodulatory therapy
* No concurrent immunomodulatory therapyReferences
Publications (0)
Data not yet available
No reference posted for this study.